[\/et_pb_text][et_pb_text _builder_version=”4.21.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n
To jointly tackle some of the major challenges in the therapy of viral hepatitis, researchers have met for a first round of strategic discussions in July 2023.<\/p>\n
<\/p>\n
<\/h3>\n
[\/et_pb_text][et_pb_text admin_label=”Turquoise box” module_class=”whitelink” _builder_version=”4.21.0″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_3_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” background_color=”#ce2525″ custom_padding=”30px|30px|30px|30px|true|true” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Improve the cure rate of HBV and CHB <\/strong><\/h2>\n[\/et_pb_text][et_pb_text _builder_version=”4.21.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n
The two research projects share the common goal to achieve functional cure of hepatitis B. For this, they investigate different aspects of the viral hepatitis B infection (HBV) and the HBV-mediated chronic disease:<\/p>\n
<\/p>\n
![\"\"](\"https:\/\/www.thervacb.eu\/wp-content\/uploads\/IP-cure-B-WebLogo.png\")
<\/a>IP-cure-B<\/a> aims to improve the cure rate in patients with chronic hepatitis B (CHB) with complementary immunomodulatory concepts. Immune interventions are investigated in two settings, in a pre-clinical model and a proof-of-concept clinical study. Innovations in immunotherapy will boost the strategic selection of the best combination for effective treatment in future clinical studies.<\/p>\n <\/p>\n
![\"TherVacB](\"https:\/\/www.thervacb.eu\/wp-content\/uploads\/RGB-TherVacB-400x146.png\")
TherVacB<\/a> provides a novel curative treatment option that aims to break immune tolerance in chronic HBV infection. This will allow the immune system to clear the virus. New vaccine components will be tested in patients with CHB in a multicentre clinical proof-of-concept study<\/a>. Finally, TherVacB aims to provide a new and affordable, safe and well tolerable treatment option to cure CHB – and a first opportunity for patients in Tanzania to be treated for hepatitis B.<\/p>\n <\/p>\n
[\/et_pb_text][et_pb_text admin_label=”Turquoise box” module_class=”whitelink” _builder_version=”4.21.0″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_3_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” background_color=”#ce2525″ custom_padding=”30px|30px|30px|30px|true|true” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Contribute to the UN\u2019s Strategic Development Goals for sustained health in endemic countries<\/strong><\/strong><\/h2>\n[\/et_pb_text][et_pb_text _builder_version=”4.21.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n
The innovations from the two projects will be instrumental to meeting the United Nation\u2019s Sustainable Development Goal 3<\/a>:<\/p>\n\n- combat hepatitis B (and D) viral infection worldwide by the year 2030,<\/li>\n
- ensure sustained health, increase the quality of life and stop stigmatization,<\/li>\n
- including in highly endemic countries that cannot afford lifelong therapies and their monitoring.<\/li>\n<\/ul>\n
<\/p>\n
[\/et_pb_text][et_pb_cta title=”Follow our journeys” _builder_version=”4.21.0″ _module_preset=”default” background_color=”#706F6F” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Stay tuned on Twitter at @ipcureb<\/a> and at @TherVacB_EU<\/a>. Learn more on the European Commission\u2019s regularly updated Project Pages for TherVacB<\/a> and IP-cure-B<\/a>. <\/span>
<\/span><\/p>\n[\/et_pb_cta][et_pb_text admin_label=”Turquoise box” module_class=”whitelink” _builder_version=”4.21.0″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_3_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” background_color=”#FFFFFF” width=”100%” custom_padding=”30px|30px|30px|30px|true|true” global_colors_info=”{}”]<\/p>\n
![\"\"](\"https:\/\/www.thervacb.eu\/wp-content\/uploads\/eu-flag-logo.jpg\")
<\/strong> TherVacB and IP-cure-B research projects have received funding from the EU’s H2020 RIA programme (GA no. 848223 and 847939).<\/span><\/span><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Experts in virology, immunology and clinical hepatitis from two research projects are working towards to cure hepatitis B: \u2018IP-cure-B \u2013 Take care of your health\u2019 and \u2018TherVacB – A therapeutic vaccine to cure Hepatitis B\u2019.To jointly tackle some of the major challenges in the therapy of viral hepatitis, researchers have met for a first round […]<\/p>\n","protected":false},"author":4,"featured_media":10755,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"
Experts in virology, immunology and clinical hepatitis from \u2018IP-cure-B \u2013 Take care of your health\u2019 and \u2018TherVacB - A therapeutic vaccine to cure Hepatitis B\u2019 research projects are working towards to cure hepatitis B.<\/h3>
To jointly tackle some of the major challenges in the therapy of viral hepatitis, researchers have met for a first round of strategic discussions in July 2023.<\/p>
Common goal to improve the cure rate of HBV and CHB <\/strong><\/h3>To achieve functional cure, the research projects investigate different aspects of viral hepatitis B infection (HBV) and the HBV-mediated chronic disease.<\/p>
IP-cure-B aims to improve the cure rate in patients with chronic hepatitis B (CHB) with complementary immunomodulatory concepts. Immune interventions are investigated in two settings, in a pre-clinical model and a proof-of-concept clinical study. IP-cure-B innovations in immunotherapy will boost strategic selection of the best combination for effective treatment in future clinical studies.<\/p>
TherVacB provides a novel curative treatment option that aims to break immune tolerance in chronic HBV infection and allow the immune system to clear the virus. Novel TherVacB vaccine components will be tested in patients with CHB in a multicentre clinical proof-of-concept study. Finally, TherVacB aims to provide a novel and affordable, safe and well tolerable curative treatment option for CHB and a first opportunity for patients in Tanzania to be treated for hepatitis B.<\/p>
Contribute to the UN\u2019s Strategic Development Goals for sustained health in endemic countries<\/strong><\/h3>The innovations from IP-cure-B and TherVacB will be instrumental to meeting the UN\u2019s Sustainable Development Goal 3:<\/p>
- combat hepatitis B (and D) viral infection worldwide by the year 2023,<\/li>
- ensure sustained health, increase the quality of life and stop stigmatization<\/li>
- including in highly endemic countries that cannot afford lifelong therapies and their monitoring.<\/li><\/ul>
\u00a0<\/p>
TherVacB and IP-cure-B research projects have received funding from the EU's H2020 RIA programme (GA no. 848223 and 847939). Learn more on the European Commission\u2019s regularly updated Project Pages for TherVacB and IP-cure-B. Follow the journeys of IP-cure-B on Twitter @ipcureb and of TherVacB on Twitter @TherVacB_EU.<\/p>
\u00a0<\/p>
\u00a0<\/p>
\u00a0<\/p>","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[58,16,1,18,13,17,15,14],"tags":[],"class_list":["post-10428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-nachrichten","category-news","category-noticias","category-noticies","category-notizia","category-nouvelles","category-14"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/posts\/10428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/comments?post=10428"}],"version-history":[{"count":1,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/posts\/10428\/revisions"}],"predecessor-version":[{"id":12546,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/posts\/10428\/revisions\/12546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/media\/10755"}],"wp:attachment":[{"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/media?parent=10428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/categories?post=10428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/tags?post=10428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/a>IP-cure-B<\/a> aims to improve the cure rate in patients with chronic hepatitis B (CHB) with complementary immunomodulatory concepts. Immune interventions are investigated in two settings, in a pre-clinical model and a proof-of-concept clinical study. Innovations in immunotherapy will boost the strategic selection of the best combination for effective treatment in future clinical studies.<\/p>\n<\/p>\n
<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Turquoise box” module_class=”whitelink” _builder_version=”4.21.0″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_3_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” background_color=”#ce2525″ custom_padding=”30px|30px|30px|30px|true|true” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.21.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n The innovations from the two projects will be instrumental to meeting the United Nation\u2019s Sustainable Development Goal 3<\/a>:<\/p>\n <\/p>\n [\/et_pb_text][et_pb_cta title=”Follow our journeys” _builder_version=”4.21.0″ _module_preset=”default” background_color=”#706F6F” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n Stay tuned on Twitter at @ipcureb<\/a> and at @TherVacB_EU<\/a>. Learn more on the European Commission\u2019s regularly updated Project Pages for TherVacB<\/a> and IP-cure-B<\/a>. <\/span> [\/et_pb_cta][et_pb_text admin_label=”Turquoise box” module_class=”whitelink” _builder_version=”4.21.0″ _module_preset=”default” text_text_color=”#FFFFFF” header_text_color=”#FFFFFF” header_2_text_color=”#FFFFFF” header_3_text_color=”#FFFFFF” header_4_text_color=”#FFFFFF” background_color=”#FFFFFF” width=”100%” custom_padding=”30px|30px|30px|30px|true|true” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Experts in virology, immunology and clinical hepatitis from two research projects are working towards to cure hepatitis B: \u2018IP-cure-B \u2013 Take care of your health\u2019 and \u2018TherVacB – A therapeutic vaccine to cure Hepatitis B\u2019.To jointly tackle some of the major challenges in the therapy of viral hepatitis, researchers have met for a first round […]<\/p>\n","protected":false},"author":4,"featured_media":10755,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":" To jointly tackle some of the major challenges in the therapy of viral hepatitis, researchers have met for a first round of strategic discussions in July 2023.<\/p> To achieve functional cure, the research projects investigate different aspects of viral hepatitis B infection (HBV) and the HBV-mediated chronic disease.<\/p> IP-cure-B aims to improve the cure rate in patients with chronic hepatitis B (CHB) with complementary immunomodulatory concepts. Immune interventions are investigated in two settings, in a pre-clinical model and a proof-of-concept clinical study. IP-cure-B innovations in immunotherapy will boost strategic selection of the best combination for effective treatment in future clinical studies.<\/p> TherVacB provides a novel curative treatment option that aims to break immune tolerance in chronic HBV infection and allow the immune system to clear the virus. Novel TherVacB vaccine components will be tested in patients with CHB in a multicentre clinical proof-of-concept study. Finally, TherVacB aims to provide a novel and affordable, safe and well tolerable curative treatment option for CHB and a first opportunity for patients in Tanzania to be treated for hepatitis B.<\/p> The innovations from IP-cure-B and TherVacB will be instrumental to meeting the UN\u2019s Sustainable Development Goal 3:<\/p> \u00a0<\/p> TherVacB and IP-cure-B research projects have received funding from the EU's H2020 RIA programme (GA no. 848223 and 847939). Learn more on the European Commission\u2019s regularly updated Project Pages for TherVacB and IP-cure-B. Follow the journeys of IP-cure-B on Twitter @ipcureb and of TherVacB on Twitter @TherVacB_EU.<\/p> \u00a0<\/p> \u00a0<\/p> \u00a0<\/p>","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[58,16,1,18,13,17,15,14],"tags":[],"class_list":["post-10428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-nachrichten","category-news","category-noticias","category-noticies","category-notizia","category-nouvelles","category-14"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/posts\/10428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/comments?post=10428"}],"version-history":[{"count":1,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/posts\/10428\/revisions"}],"predecessor-version":[{"id":12546,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/posts\/10428\/revisions\/12546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/media\/10755"}],"wp:attachment":[{"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/media?parent=10428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/categories?post=10428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.thervacb.eu\/it\/wp-json\/wp\/v2\/tags?post=10428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} TherVacB<\/a> provides a novel curative treatment option that aims to break immune tolerance in chronic HBV infection. This will allow the immune system to clear the virus. New vaccine components will be tested in patients with CHB in a multicentre clinical proof-of-concept study<\/a>. Finally, TherVacB aims to provide a new and affordable, safe and well tolerable treatment option to cure CHB – and a first opportunity for patients in Tanzania to be treated for hepatitis B.<\/p>\nContribute to the UN\u2019s Strategic Development Goals for sustained health in endemic countries<\/strong><\/strong><\/h2>\n
\n
<\/span><\/p>\n<\/strong> TherVacB and IP-cure-B research projects have received funding from the EU’s H2020 RIA programme (GA no. 848223 and 847939).<\/span><\/span><\/p>\nExperts in virology, immunology and clinical hepatitis from \u2018IP-cure-B \u2013 Take care of your health\u2019 and \u2018TherVacB - A therapeutic vaccine to cure Hepatitis B\u2019 research projects are working towards to cure hepatitis B.<\/h3>
Common goal to improve the cure rate of HBV and CHB <\/strong><\/h3>
Contribute to the UN\u2019s Strategic Development Goals for sustained health in endemic countries<\/strong><\/h3>